FUJIFILM Diosynth Biotechnologies
Thousand Oaks, CA
Research Triangle Park, NC
College Station, TX
Holly Springs, NC
About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies is an industry leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting our partners in the biopharmaceutical industry with the development and production of their biologic, vaccines and gene therapies.
With over 30 years of experience in process development and cGMP manufacturing, a dedicated staff of over 2,000 and a reputation for excellent customer service, flexibility and responsiveness, we’ve become a trusted partner to some of the most prominent biotech developers and pharmaceutical companies in the industry.
Our Process Development experience includes the development of processes for molecules expressed via fermentation (e.g., E. coli, P. pastoris), cell culture systems including CHO, HEK, Vero, MDCK, EB66 and insect cells, and from transgenic sources.
Our network expands within five development and manufacturing facilities located in Teesside, United Kingdom; Research Triangle Park, North Carolina, USA; College Station, Texas, Thousand Oaks CA USA and Hillerød, Denmark.
Join Us - We are Hiring!
60 articles with FUJIFILM Diosynth Biotechnologies
The past few weeks have seen changes that will impact the biopharma industry surrounding salaries and pay. To learn about job opportunities at some of the industry's top companies, see inside.
Newly-launched Massachusetts biomanufacturing facility will be something like a conveyor belt from the academic bench to the early startup.
FUJIFILM Diosynth Biotechnologies Enters Into an Agreement with Argenx to Manufacture Efgartigimod, a monoclonal antibody (mAb) for the Treatment of Severe Autoimmune Diseases
FUJIFILM Diosynth Biotechnologies announced an agreement with argenx to manufacture efgartigimod, a monoclonal antibody fragment to target the neonatal Fc receptor, in patients with severe autoimmune disease.
FUJIFILM Dyosynth Biotechnologies, Taysha Gene Therapies, Veravas highlight innovation stemming from the Lone Star state. BioSpace takes a deep dive into these and other Texas innovators.
Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.
The $1.6-billion infusion into its subsidiary is Fujifilm’s latest move to establish a more robust presence in the cell culture manufacturing space.
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
Atara Biotherapeutics, Inc. today announced FUJIFILM Diosynth Biotechnologies has completed the acquisition of Atara’s cell therapy manufacturing facility in Thousand Oaks.
FUJIFILM Healthcare Americas Corporation, a leading provider of enterprise imaging and informatics solutions, has ranked #1 in KLAS Research’s 2022 ‘Best in KLAS’ report for Fujifilm’s Synapse VNA and Synapse Cardiology PACS in the United States, and Synapse Radiology PACS in Latin America.
Fujifilm announced that it is acquiring Atara Biotherapeutics' cell therapy manufacturing facility in California for $100 million.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
Biopharma companies are eying the establishment of new facilities across the globe that will bolster their manufacturing strategies. BioSpace rounds up some of the latest announcements.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
The life sciences industry continues to be one of the fastest growing industries in the world as the end of the year draws near.
The project will be one of the largest construction projects in North Carolina, with about 2 million sq. ft. of space. It is expected to bring in 725 new jobs in Wake County over the next five years.
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development and Manufacturing of Gene Therapies for Genetic Diseases
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies today announced a strategic collaboration to support the development and manufacturing of LEXEO’s AAV-mediated gene therapies.
FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke
The signing of the manufacturing agreement with NeuExcell showcases our flexibility in supporting biotech companies of all sizes, and our focused commitment to enabling NeuExcell to reach the full potential of their innovative gene technology platform on accelerated timelines.
The cash infusion will support the growth of its manufacturing capabilities in the US and the UK and the demands for gene therapies, antibodies, and vaccines such as COVID-19.
Here’s a recap of companies announcing facility expansions this past month and life sciences job creations across the nation.
Morrisville, North Carolina, has reason to hope that it may be the beneficiary of Fujifilm’s next major investment, a $2 Billion USD large-scale cell culture manufacturing site which the company said will be located near one of its current facilities.
The new process development and manufacturing facility will focus on viral vectors and advanced therapies. It is the third location for Diosynth’s CDMO viral vector services.